ASTELLAS PHARMA

astellas-pharma-logo

Astellas Pharma Inc. is a Japan-based pharmaceutical company that operates its business in more than 70 countries around the world. It has approximately 16,000 employees, and its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation. In its FY2019 financial results, revenue achieved about 1,300 billion yen (ca.$12 billion*), and R&D expenses... were about 220 billion yen (ca.$1.9 billion*). Astellas' competitiveness comes from its own innovativeness in R&D and extensive network featuring cutting-edge technology garnered through proactive collaborations with academia, bio-ventures, and pharmaceutical companies worldwide. Its R&D activities are managed and promoted by functional centers in the U.S., Japan, and Asia, which enhance agility and efficiency of projects through parallel developments globally. Astellas established the “Focus Area Approach” as its R&D strategy. This approach focuses on building sustainable and expandable drug discovery by selecting the best combination of biology, modality/technology, and disease. The company has identified four prioritized research areas, Blindness & Regeneration, Mitochondria Biology, Genetic Regulation, Immuno-Oncology, named “Primary Focus” where it focuses its resource to strategically expand its pipeline. One of the Astellas’ key focuses that support the strategy is collaborations with academic labs and various pharmaceutical companies, including start-ups. Dedicated teams have been assigned to maximize the value of respective collaborations. These include Astellas Innovation Management, which promotes intaking early-stage innovations, Business Development, which identifies opportunities for inward/outward transactions and executes deals and manages subsequent alliances, and Astellas Venture Management, a corporate venture capital that makes private equity investments in early-stage biotech start-ups in an attempt to potentially reinforce Astellas’ pipeline. In drug discovery activities, the R&D pipeline programs have been reinforced by incorporating external cutting-edge science. In recent years in particular, advanced technologies in areas such as cell therapy and genetic regulation have been added to Astellas’ capabilities. Astellas has also been successful in M&As, including Audentes Therapeutics, Xyphos Biosciences, Nanna Therapeutics, Universal Cells, Ocata Therapeutics, and Mitobridge for unique scientific features. Astellas has demonstrated a strong footprint in late-stage clinical trials and commercialization of its strategic products. In the past three years, it successfully launched three new products (XOSPATA, Evrenzo and PADCEV) and expanded indications of XTANDI worldwide by realizing excellent management of each clinical trial program. Astellas also achieved annual sales of 754.5 billion yen (ca.$6.9 billion*) with XTANDI, Betanis / Myrbetriq / BETMIGA, and Prograf in FY2019 with a strong focus on delivering value through improving patient access and outcomes in the associated therapy areas. Another remarkable approach that Astellas is taking is creating new healthcare solutions beyond medicine based on the existing expertise and knowledge in its Rx business, combined with adjacent technologies from partners. Astellas values research outcomes from all partners and is willing to realize untapped value thereof by collaborating with a partner and maximizing the value of assets by using Astellas’ capability (e.g., funding, facilities, human resources, and know-how). Openness and flexibility in designing alliance mechanisms (e.g. tailored joint study programs and financial arrangements) will help the parties to realize executing a deal in a timely manner. Astellas is committed to creating medical solutions in order to turn innovative science into value for patients and incorporating capabilities of partners. *The exchange rate for the yen, 1USD: 109yen

#People #Financial #Event #Website #More

ASTELLAS PHARMA

Social Links:

Industry:
Biotechnology Health Care Medical

Founded:
2005-04-01

Address:
Tokyo, Tokyo, Japan

Country:
Japan

Website Url:
http://www.astellas.com

Total Employee:
10001+

Status:
Active

Contact:
(813) 324-4300

Total Funding:
0

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Wordpress Plugins Mobile Non Scaleable Content Sitelinks Search Box IPv6


Current Employees Featured

not_available_image

Ana C. Ward
Ana C. Ward Vice President - Head of Affiliate Engagement @ Astellas Pharma
Vice President - Head of Affiliate Engagement
2021-10-01

not_available_image

Atsushi Kamide
Atsushi Kamide Corporate Executive @ Astellas Pharma
Corporate Executive

not_available_image

Toshihiko Iwata
Toshihiko Iwata Corporate Executive @ Astellas Pharma
Corporate Executive

takeru-furuya_image

Takeru Furuya
Takeru Furuya Associate Director, Medicinal Chemistry @ Astellas Pharma
Associate Director, Medicinal Chemistry
2020-09-01

not_available_image

Kenji Sumi
Kenji Sumi Corporate Executive @ Astellas Pharma
Corporate Executive

elizabeth-oubre_image

Elizabeth Oubre
Elizabeth Oubre Manager, Marketing Operations, Market Access & Commercial Capabilities @ Astellas Pharma
Manager, Marketing Operations, Market Access & Commercial Capabilities
2021-10-01

not_available_image

Yoshihiko Hatanaka
Yoshihiko Hatanaka Representative Director, President and Chief Executive Officer @ Astellas Pharma
Representative Director, President and Chief Executive Officer

amanda-hart_image

Amanda Hart
Amanda Hart Head, Global Business and Market Analytics @ Astellas Pharma
Head, Global Business and Market Analytics
2019-10-01

not_available_image

Hirofumi Seki
Hirofumi Seki Corporate Executive @ Astellas Pharma
Corporate Executive

not_available_image

Roger Gay
Roger Gay Senior Dircector of Product Development @ Astellas Pharma
Senior Dircector of Product Development
2016-02-01

Founder


erik-karrer_image

Erik Karrer

Stock Details


Company's stock symbol is TYO:4503

Acquisitions List

Date Company Article Price
2020-10-15 Iota Biosciences Iota Biosciences acquired by Astellas Pharma 127.5 M USD
2020-04-21 Nanna Therapeutics Nanna Therapeutics acquired by Astellas Pharma 12 M GBP
2019-12-26 Xyphos Biosciences Xyphos Biosciences acquired by Astellas Pharma N/A
2019-12-02 Audentes Therapeutics Audentes Therapeutics acquired by Astellas Pharma 3 B USD
2018-12-14 Potenza Therapeutics Potenza Therapeutics acquired by Astellas Pharma 405 M USD
2018-08-10 Quethera Quethera acquired by Astellas Pharma 109 M USD
2018-02-13 Universal Cells Inc. Universal Cells Inc. acquired by Astellas Pharma N/A
2017-12-01 Mitobridge Mitobridge acquired by Astellas Pharma N/A
2017-04-02 Ogeda Ogeda acquired by Astellas Pharma 500 M EUR
2016-10-28 Ganymed Pharmaceuticals Ganymed Pharmaceuticals acquired by Astellas Pharma 1.4 B USD

Investors List

national-institute-on-drug-abuse-nida_image

National Institute on Drug Abuse (NIDA)

National Institute on Drug Abuse (NIDA) investment in Grant - Astellas Pharma

Investments List

Date Company Article Money raised
2021-11-04 The National Comprehensive Cancer Network (NCCN) Astellas Pharma investment in Grant - The National Comprehensive Cancer Network (NCCN) N/A
2019-10-06 LabCentral Astellas Pharma investment in Corporate Round - LabCentral 13 M USD
2018-12-27 Iota Biosciences Astellas Pharma investment in Series A - Iota Biosciences 15 M USD
2017-11-15 Catalia Health Astellas Pharma investment in Grant - Catalia Health 12.5 K USD
2013-10-04 Mitobridge Astellas Pharma investment in Series A - Mitobridge 5.22 M USD
2012-04-24 Telsar Pharma Astellas Pharma investment in Series A - Telsar Pharma 14 M USD
2008-06-05 CoMentis Astellas Pharma investment in Series D - CoMentis 20 M USD
2005-02-17 FibroGen Astellas Pharma investment in Venture Round - FibroGen 100 M USD

Newest Events participated

smit-congress-2019_event_image Participated in SMIT CONGRESS 2019 on 2019-10-10 as exhibitor

smit-congress-2019_event_image Participated in SMIT CONGRESS 2019 on 2019-10-10 as sponsor

webitfestival-europe_event_image Participated in Webit.Festival Europe on 2018-06-25 as exhibitor

redefining-early-stage-investments-resi-conference-boston_event_image Participated in Redefining Early Stage Investments (RESI) Conference @ Boston on 2018-06-04 as sponsor

Key Employee Changes

Date New article
2022-08-05 Chutes & Ladders—Astellas shakes up leadership with two new C-suite execs

Official Site Inspections

http://www.astellas.com Semrush global rank: 157.65 K Semrush visits lastest month: 534.52 K

  • Host name: 23.96.32.128
  • IP address: 23.96.32.128
  • Location: Washington United States
  • Latitude: 38.7095
  • Longitude: -78.1539
  • Metro Code: 511
  • Timezone: America/New_York
  • Postal: 22747

Loading ...

More informations about "Astellas Pharma" on Search Engine